Related Experiment Video
Updated: Jul 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Pharmacotherapy of atrial fibrillation: an old option with new possibilities
Sabine Janko1, Uwe Dorwarth, Ellen Hoffmann
1Heart Center Munich-Bogenhausen, Department of Cardiology and Intensive Care Unit, Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Strasse 77, 89125 Munich, Germany.
Background:
Atrial fibrillation is the most common sustained arrhythmia observed worldwide. Despite modern ablative treatment options, pharmacotherapy remains the first-line therapy in patients with atrial fibrillation.
Objective:
Based on recently published guidelines for the management of atrial fibrillation, the present paper reviews the current and emerging concepts of pharmacotherapy in atrial fibrillation.
Methods:
A MEDLINE search was conducted using the keyword 'atrial fibrillation' and 'drug therapy'. The reviewed literature included clinical trials and published reviews as well as clinical guidelines.
Results:
The mainstay of atrial fibrillation therapy is the prevention of thromboembolic events. With growing knowledge of the pathophysiology of atrial fibrillation new drug targets have been identified that promise improved outcomes in atrial fibrillation management and this will allow individual drug treatment in the near future.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

